Contact
searchSearch
HMP Global

Rheumatoid Arthritis Specialty Channel

News
US Observational Data Show Variable Real-World Outcomes With JAK Inhibitors in RA
01/19/2026
Juliet Gallagher
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is...
01/19/2026
First Report Managed Care
News
Specialist Access Eliminates Racial Gaps in Rheumatoid Arthritis DMARD Use
01/12/2026
Lisa Kuhns, PhD, MD
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to...
01/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
Videos
Evolving Strategies in RA Treatment: Real-World Insights and Access Challenges
06/09/2025
Jonathan Kay, MD; Julie Baak; Juliet Gallagher
This expert roundtable, hosted by First Report Managed Care, explores the evolving rheumatoid arthritis (RA) treatment landscape, highlighting advancements in therapeutic options, challenges with payer-driven access and reimbursement, and the...
This expert roundtable, hosted by First Report Managed Care, explores the evolving rheumatoid arthritis (RA) treatment landscape, highlighting advancements in therapeutic options, challenges with payer-driven access and reimbursement, and the...
This expert roundtable, hosted...
06/09/2025
First Report Managed Care
Formulary Frontlines®
Comparative Review of RA Biologics and DMARDs Coverage Across 3 Major Health Plans
05/23/2025
Danielle Sposato; Juliet Gallagher
Our latest Formulary Frontlines report analyzes how Blue Cross Blue Shield, Cigna, and UnitedHealthcare structure coverage for RA biologics and DMARDs, revealing key differences in tiering, utilization management, and biosimilar strategy....
Our latest Formulary Frontlines report analyzes how Blue Cross Blue Shield, Cigna, and UnitedHealthcare structure coverage for RA biologics and DMARDs, revealing key differences in tiering, utilization management, and biosimilar strategy....
Our latest Formulary Frontlines...
05/23/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care
News
Urban Residents With Arthritis Access More In-Person Care Than Rural Counterparts
04/24/2025
Lisa Kuhns, PhD, MD
Individuals with rheumatoid arthritis (RA) and osteoarthritis (OA) living in rural areas access significantly less in-person health care than those in urban settings, according to a study published in Arthritis Care & Research.
Individuals with rheumatoid arthritis (RA) and osteoarthritis (OA) living in rural areas access significantly less in-person health care than those in urban settings, according to a study published in Arthritis Care & Research.
Individuals with rheumatoid...
04/24/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos Interview

What's New?

News
US Observational Data Show Variable Real-World Outcomes With JAK Inhibitors in RA
01/19/2026
Juliet Gallagher
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is increasingly used to complement randomized controlled trial data in rheumatoid arthritis treatment decision-making. A new study synthesized observational studies evaluating the real-world effectiveness of Janus...
Real-world evidence (RWE) is...
01/19/2026
First Report Managed Care
News
Specialist Access Eliminates Racial Gaps in Rheumatoid Arthritis DMARD Use
01/12/2026
Lisa Kuhns, PhD, MD
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to modern rheumatoid arthritis (RA) therapies persist across the United States, but disappear among patients who reach rheumatology care, according to study results published in The Journal of Rheumatology.
Racial inequities in access to...
01/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
Videos
Evolving Strategies in RA Treatment: Real-World Insights and Access Challenges
06/09/2025
Jonathan Kay, MD; Julie Baak; Juliet Gallagher
This expert roundtable, hosted by First Report Managed Care, explores the evolving rheumatoid arthritis (RA) treatment landscape, highlighting advancements in therapeutic options, challenges with payer-driven access and reimbursement, and the...
This expert roundtable, hosted by First Report Managed Care, explores the evolving rheumatoid arthritis (RA) treatment landscape, highlighting advancements in therapeutic options, challenges with payer-driven access and reimbursement, and the...
This expert roundtable, hosted...
06/09/2025
First Report Managed Care
Formulary Frontlines®
Comparative Review of RA Biologics and DMARDs Coverage Across 3 Major Health Plans
05/23/2025
Danielle Sposato; Juliet Gallagher
Our latest Formulary Frontlines report analyzes how Blue Cross Blue Shield, Cigna, and UnitedHealthcare structure coverage for RA biologics and DMARDs, revealing key differences in tiering, utilization management, and biosimilar strategy....
Our latest Formulary Frontlines report analyzes how Blue Cross Blue Shield, Cigna, and UnitedHealthcare structure coverage for RA biologics and DMARDs, revealing key differences in tiering, utilization management, and biosimilar strategy....
Our latest Formulary Frontlines...
05/23/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use